221 related articles for article (PubMed ID: 36890041)
41. PIWIL1 governs the crosstalk of cancer cell metabolism and immunosuppressive microenvironment in hepatocellular carcinoma.
Wang N; Tan HY; Lu Y; Chan YT; Wang D; Guo W; Xu Y; Zhang C; Chen F; Tang G; Feng Y
Signal Transduct Target Ther; 2021 Feb; 6(1):86. PubMed ID: 33633112
[TBL] [Abstract][Full Text] [Related]
42. Multiomics characterization of fatty acid metabolism for the clinical management of hepatocellular carcinoma.
Huang X; Su B; Li M; Zhou Y; He X
Sci Rep; 2023 Dec; 13(1):22472. PubMed ID: 38110715
[TBL] [Abstract][Full Text] [Related]
43. Evidence of aberrant lipid metabolism in hepatitis C and hepatocellular carcinoma.
Wu JM; Skill NJ; Maluccio MA
HPB (Oxford); 2010 Nov; 12(9):625-36. PubMed ID: 20961371
[TBL] [Abstract][Full Text] [Related]
44. Targeting non-coding RNAs and N
Wu L; Zhang Y; Ren J
Biochem Pharmacol; 2024 May; 223():116153. PubMed ID: 38513741
[TBL] [Abstract][Full Text] [Related]
45. LINC01554-Mediated Glucose Metabolism Reprogramming Suppresses Tumorigenicity in Hepatocellular Carcinoma via Downregulating PKM2 Expression and Inhibiting Akt/mTOR Signaling Pathway.
Zheng YL; Li L; Jia YX; Zhang BZ; Li JC; Zhu YH; Li MQ; He JZ; Zeng TT; Ban XJ; Yuan YF; Li Y; Guan XY
Theranostics; 2019; 9(3):796-810. PubMed ID: 30809309
[No Abstract] [Full Text] [Related]
46. Novel insights into small open reading frame-encoded micropeptides in hepatocellular carcinoma: A potential breakthrough.
Zhang Q; Liu L
Cancer Lett; 2024 Apr; 587():216691. PubMed ID: 38360139
[TBL] [Abstract][Full Text] [Related]
47. Non-coding RNAs in hepatitis B or C-associated hepatocellular carcinoma: potential diagnostic and prognostic markers and therapeutic targets.
Zhang Q; Pu R; Du Y; Han Y; Su T; Wang H; Cao G
Cancer Lett; 2012 Aug; 321(1):1-12. PubMed ID: 22425745
[TBL] [Abstract][Full Text] [Related]
48. The Hippo pathway in hepatocellular carcinoma: Non-coding RNAs in action.
Shi X; Zhu HR; Liu TT; Shen XZ; Zhu JM
Cancer Lett; 2017 Aug; 400():175-182. PubMed ID: 28461246
[TBL] [Abstract][Full Text] [Related]
49. Long non-coding RNA CASC15 is upregulated in hepatocellular carcinoma and facilitates hepatocarcinogenesis.
He T; Zhang L; Kong Y; Huang Y; Zhang Y; Zhou D; Zhou X; Yan Y; Zhang L; Lu S; Zhou J; Wang W
Int J Oncol; 2017 Dec; 51(6):1722-1730. PubMed ID: 29075788
[TBL] [Abstract][Full Text] [Related]
50. Dysregulated signaling hubs of liver lipid metabolism reveal hepatocellular carcinoma pathogenesis.
Lee S; Mardinoglu A; Zhang C; Lee D; Nielsen J
Nucleic Acids Res; 2016 Jul; 44(12):5529-39. PubMed ID: 27216817
[TBL] [Abstract][Full Text] [Related]
51. Analysis of the impact of fatty acid metabolism on immunotherapy for hepatocellular carcinoma.
Wang J; Jin X
Ann Hepatol; 2023; 28(6):101148. PubMed ID: 37643716
[TBL] [Abstract][Full Text] [Related]
52. Long Noncoding RNAs Act as Novel Biomarkers for Hepatocellular Carcinoma: Progress and Prospects.
Bao H; Su H
Biomed Res Int; 2017; 2017():6049480. PubMed ID: 28835896
[TBL] [Abstract][Full Text] [Related]
53. The Role of Extracellular Vesicles as Shuttles of RNA and Their Clinical Significance as Biomarkers in Hepatocellular Carcinoma.
Costanzi E; Simioni C; Varano G; Brenna C; Conti I; Neri LM
Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34207985
[TBL] [Abstract][Full Text] [Related]
54. Hippocalcin-Like 1 blunts liver lipid metabolism to suppress tumorigenesis via directly targeting RUVBL1-mTOR signaling.
Chen T; Yuan Z; Lei Z; Duan J; Xue J; Lu T; Yan G; Zhang L; Liu Y; Li Q; Zhang Y
Theranostics; 2022; 12(17):7450-7464. PubMed ID: 36438486
[No Abstract] [Full Text] [Related]
55. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
56. Dysregulation of non-coding RNAs mediates cisplatin resistance in hepatocellular carcinoma and therapeutic strategies.
Xu XF; Yang XK; Song Y; Chen BJ; Yu X; Xu T; Chen ZL
Pharmacol Res; 2022 Feb; 176():105906. PubMed ID: 34543740
[TBL] [Abstract][Full Text] [Related]
57. Deep sequencing of small RNA transcriptome reveals novel non-coding RNAs in hepatocellular carcinoma.
Law PT; Qin H; Ching AK; Lai KP; Co NN; He M; Lung RW; Chan AW; Chan TF; Wong N
J Hepatol; 2013 Jun; 58(6):1165-73. PubMed ID: 23376363
[TBL] [Abstract][Full Text] [Related]
58. ACSL4 reprograms fatty acid metabolism in hepatocellular carcinoma via c-Myc/SREBP1 pathway.
Chen J; Ding C; Chen Y; Hu W; Yu C; Peng C; Feng X; Cheng Q; Wu W; Lu Y; Xie H; Zhou L; Wu J; Zheng S
Cancer Lett; 2021 Apr; 502():154-165. PubMed ID: 33340617
[TBL] [Abstract][Full Text] [Related]
59. The switch triggering the invasion process: Lipid metabolism in the metastasis of hepatocellular carcinoma.
Zhang J; Zhang Z; Wu Z; Wang Y; Zhang Z; Xia L
Chin Med J (Engl); 2024 Jun; 137(11):1271-1284. PubMed ID: 38738689
[TBL] [Abstract][Full Text] [Related]
60. Long noncoding RNA AWPPH promotes hepatocellular carcinoma progression through YBX1 and serves as a prognostic biomarker.
Zhao X; Liu Y; Yu S
Biochim Biophys Acta Mol Basis Dis; 2017 Jul; 1863(7):1805-1816. PubMed ID: 28428004
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
